Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Company profile
Ticker
REGN
Exchange
Website
CEO
Leonard Schleifer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
REGENERON PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Eastside Campus Holdings LLC • Loop Road Holdings LLC • Old Saw Mill Holdings LLC • OSMR Holdings • Regeneron Assurance, Inc. • Regeneron Atlantic Holdings • Regeneron Belgium BV • Regeneron Canada Company • Regeneron Capital International B.V. • Regeneron Genetics Center LLC ...
IRS number
133444607
REGN stock data
News

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
24 Jun 22
Intellia and Regeneron Present Updated Interim Data From Phase 1 Study Of CRISPR-based NTLA-2001 For The Treatment Of Transthyretin Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
24 Jun 22
Regeneron Pharmaceuticals Whale Trades Spotted
17 Jun 22
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today
15 Jun 22
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
8 Jun 22
Press releases
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
24 Jun 22
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
7 Jun 22
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
2 Jun 22
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
2 Jun 22
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
31 May 22
Analyst ratings and price targets
Current price
Average target
$683.14
Low target
$536.00
High target
$760.00
Jefferies
Initiated
$536.00
Morgan Stanley
Maintains
$610.00
Wells Fargo
Maintains
$735.00
Argus Research
Maintains
$760.00
SVB Leerink
Initiated
$738.00
RBC Capital
Maintains
$658.00
Barclays
Maintains
$745.00
Calendar
4 May 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jun 22 | Marion McCourt | Common Stock | Sell | Dispose S | No | Yes | 669.51 | 1,100 | 736.46K | 19,644 |
1 Jun 22 | Marion McCourt | Common Stock | Option exercise | Acquire M | No | Yes | 342.93 | 1,100 | 377.22K | 20,744 |
1 Jun 22 | Marion McCourt | NQSO Common Stock | Option exercise | Dispose M | No | Yes | 342.93 | 1,100 | 377.22K | 3,800 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 670.49 | 57 | 38.22K | 58,470 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 669.12 | 153 | 102.38K | 58,527 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 668.68 | 180 | 120.36K | 58,680 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 667.49 | 154 | 102.79K | 58,860 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 666.23 | 352 | 234.51K | 59,014 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 665.36 | 126 | 83.84K | 59,366 |
17 May 22 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 664.32 | 428 | 284.33K | 59,492 |
Institutional ownership, Q1 2022
84.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1039 |
Opened positions | 127 |
Closed positions | 124 |
Increased positions | 363 |
Reduced positions | 385 |
13F shares | Current |
---|---|
Total value | 63.8B |
Total shares | 91.52M |
Total puts | 1.53M |
Total calls | 923.16K |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 9.98M | $6.97B |
BLK Blackrock | 9.58M | $6.69B |
Vanguard | 8.36M | $5.84B |
Capital World Investors | 5.95M | $4.16B |
STT State Street | 5.13M | $3.58B |
JPM JPMorgan Chase & Co. | 4.96M | $3.47B |
Wellington Management | 2.89M | $2.02B |
Loomis Sayles & Co L P | 2.55M | $1.78B |
Dodge & Cox | 2.24M | $1.56B |
Geode Capital Management | 2.09M | $1.46B |
Financial report summary
?Competition
Novelion Therapeutics • Biocryst Pharmaceuticals • IRIDEX • Seagen • Cytokinetics • Achillion Pharmaceuticals • Curis • Macrogenics • Molecular Templates • MedicinovaRisks
- Our business may be further adversely affected by the effects of the COVID-19 pandemic.
- We face risks related to the development, manufacturing, and commercialization of REGEN-COV and "next generation" monoclonal antibodies targeting SARS-CoV-2.
- We are substantially dependent on the success of EYLEA and Dupixent.
- If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.
- We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.
- Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.
- The commercial success of our products and product candidates is subject to significant competition.
- We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.
- Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.
- We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.
- We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.
- If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.
- If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.
- Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.
- Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.
- Successful development of our current and future product candidates is uncertain.
- Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.
- Many of our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.
- We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.
- Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.
- If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.
- We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.
- Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.
- We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.
- Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.
- Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.
- If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.
- Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.
- Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.
- If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.
- Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.
- Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.
- Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.
- Changes in laws and regulations affecting the healthcare industry could adversely affect our business.
- Risks associated with our operations outside the United States could adversely affect our business.
- We may incur additional tax liabilities related to our operations.
- We face risks related to the personal data we collect, process, and share.
- Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.
- If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.
- If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.
- Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.
- We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.
- Significant disruptions of information technology systems or breaches of data security could adversely affect our business.
- We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.
- Our indebtedness could adversely impact our business.
- Changes in foreign currency exchange rates could have a material adverse effect on our operating results.
- Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.
- Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect our business, operating results, and financial condition.
- Our stock price is extremely volatile.
- Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.
- There can be no assurance that we will repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.
- Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.
- The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
ABPA, Adicet, adolescent, agent, Alzheimer, amortization, annum, Apotex, APP, armed, asset, ATTR, BA, BAL, Bank, Bio, Blue, bronchopulmonary, BSC, Chair, Checkmate, choose, climate, Commissioner, conflict, consummated, consummation, cybersecurity, cyberwarfare, deceptive, decree, Delta, desensitization, discarded, dominant, dyspnea, evacuate, evacuation, exploit, Fast, fianlimab, FOP, forward, fourth, frequency, futility, gas, German, headcount, helminth, historically, HMO, Horizon, incident, invasion, Jersey, kidney, lapse, led, lessor, line, main, markedly, military, minimum, misled, modified, modify, nausea, novelty, OECD, Ohio, omalizumab, Omicron, orphan, parasitic, pertaining, PHI, prophylactic, pyrexia, reallocation, reauthorized, redesign, refractory, relocate, rent, RGC, ROW, Russia, Russian, safeguard, safer, sentence, Shield, shift, spike, structure, subsection, susceptibility, susceptible, syndicate, synthetic, tender, tendering, tissue, Track, trajectory, Transplant, Ukraine, Ultragenyx, unpaid, Vabysmo, variant, violence, Voluntarily, waiting, warfare, withdrew
Removed:
absence, add, Aimmune, angiogenic, asymptomatic, Aventisub, backed, bear, Bet, birch, bond, Cap, cat, Chairman, Chengdu, CHMP, clear, committee, conditionally, confirmed, death, declared, Delaware, demonstrating, denying, designee, diagnose, disapprove, dismissing, dose, enabling, estoppel, expressly, Fel, foot, forbidding, France, fusion, Genzyme, globe, hand, Hereditary, hip, hospitalization, household, identifiable, immunotherapy, index, indexed, individually, invalidating, invest, IRS, Italy, IV, jury, Kanghong, kg, LCA, lesser, letter, lowest, moot, ordinary, outbreak, owe, owed, oxygen, PANORAMA, permit, personally, placebo, polyneuropathy, prejudice, prepayment, Presidential, progression, projected, PTAB, rapidly, reached, recommending, recruiting, recur, rejecting, remanded, renewed, resident, returned, reversed, rollout, RSV, rulemaking, run, showing, smaller, solicitation, Spain, sponsored, steering, stipulation, stopping, Street, strongly, suptavumab, survival, symptom, symptomatic, terminal, transitional, uninfected, vacated, verdict, virology, Wall, weighing
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 22
8-K
Entry into a Material Definitive Agreement
2 Jun 22
8-K
Regeneron Reports First Quarter 2022 Financial and Operating Results
4 May 22
8-K
Entry into a Material Definitive Agreement
8 Mar 22
8-K
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
4 Feb 22
8-K
Results of Operations and Financial Condition
10 Jan 22
8-K
Regeneron Reports Third Quarter 2021 Financial and Operating Results
4 Nov 21
8-K
Entry into a Material Definitive Agreement
16 Sep 21
8-K
Regeneron Reports Second Quarter 2021 Financial and Operating Results
5 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 21
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
31 May 22
SC TO-T/A
Third party tender offer statement (amended)
20 May 22
SC TO-T/A
Third party tender offer statement (amended)
11 May 22
SC TO-T
Third party tender offer statement
2 May 22
SC TO-C
Information about tender offer
19 Apr 22
S-3ASR
Automatic shelf registration
4 Nov 21
424B5
Prospectus supplement for primary offering
10 Aug 20
FWP
Free writing prospectus
7 Aug 20
424B3
Prospectus supplement
7 Aug 20
S-8
Registration of securities for employees
16 Jun 20
Proxies
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEFA14A
Additional proxy soliciting materials
3 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
8 Jun 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
Other
UPLOAD
Letter from SEC
3 Jan 21
CORRESP
Correspondence with SEC
6 Dec 20
UPLOAD
Letter from SEC
19 Nov 20
CT ORDER
Confidential treatment order
15 Jul 20
CT ORDER
Confidential treatment order
8 Oct 19
CT ORDER
Confidential treatment order
14 May 19
CT ORDER
Confidential treatment order
9 May 19
CT ORDER
Confidential treatment order
7 May 19
CT ORDER
Confidential treatment order
26 Jul 18
CT ORDER
Confidential treatment order
8 Jan 18
Ownership
4
REGENERON PHARMACEUTICALS / Marion McCourt ownership change
3 Jun 22
4
REGENERON PHARMACEUTICALS / ANDREW J MURPHY ownership change
18 May 22
4
REGENERON PHARMACEUTICALS / ARTHUR F RYAN ownership change
3 May 22
4
REGENERON PHARMACEUTICALS / Marion McCourt ownership change
3 May 22
4
REGENERON PHARMACEUTICALS / Robert E Landry ownership change
11 Apr 22
4
REGENERON PHARMACEUTICALS / JOSEPH J LAROSA ownership change
11 Apr 22
4
REGENERON PHARMACEUTICALS / Christopher R. Fenimore ownership change
11 Apr 22
4
REGENERON PHARMACEUTICALS / Bonnie L Bassler ownership change
11 Apr 22
4
REGENERON PHARMACEUTICALS / LEONARD S SCHLEIFER ownership change
7 Apr 22
4
REGENERON PHARMACEUTICALS / Marion McCourt ownership change
4 Apr 22
Patents
Utility
Non-human Animals Having a Humanized TSLP Gene, a Humanized TSLP Receptor Gene, And/or a Humanized IL7RA Gene
23 Jun 22
Disclosed herein are rodents (such as, but not limited to, mice and rats) genetically modified to comprise a humanized Tslp gene, a humanized Tslpr gene, a humanized 117ra gene, or a combination thereof.
Utility
Auto-injector and Related Methods of Use
23 Jun 22
An auto-injector may include a housing having a longitudinal axis and a transverse axis, the housing having a shorter dimension along the transverse axis than along the longitudinal axis, wherein the transverse axis is perpendicular to the longitudinal axis; a flowpath having a first end and a second end; and a container enclosing a first fluid, the container extending from a first end toward a second end along or parallel to the longitudinal axis and being movable from a first position to a second position along or parallel to the longitudinal axis, the container being fluidly isolated from the flowpath in the first position and fluidly connected to the flowpath in the second position.
Utility
Compositions and Methods for Internalizing Enzymes
23 Jun 22
Compositions and methods for treating enzyme-deficiency diseases are disclosed.
Utility
Novel Antigen Binding Molecule Formats
23 Jun 22
Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
Utility
Nucleic Acids Encoding Anchor Modified Antibodies and Uses Thereof
23 Jun 22
Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest.
Transcripts
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
4 Feb 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
5 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
6 Feb 20
Reddit threads
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
[Weekly Megathread] Markets and Value Stock Ideas, Week of June 20, 2022
20 Jun 22
What are some "boring" US stocks that consistently deliver strong results and have a strong balance sheet?
19 Jun 22
Rate My Portfolio - r/Stocks Quarterly Thread June 2022
1 Jun 22
What's your cash percentage and why?
31 May 22
r/Stocks Daily Discussion & Technicals Tuesday - May 31, 2022
31 May 22
r/Stocks Daily Discussion Monday - May 30, 2022
30 May 22
[Weekly Megathread] Markets and Value Stock Ideas, Week of May 30, 2022
30 May 22
Anybody else just buying MSFT?
15 May 22
(5/4) Wednesday's Pre-Market Stock Movers & News
4 May 22